What is JenaValve?
Founded in 1995 and headquartered in Irvine, California, JenaValve is a pioneer in the medical device industry, specifically focusing on the development of native aortic valve leaflets. The company operates at the intersection of advanced engineering and clinical medicine, aiming to provide innovative solutions for patients suffering from aortic valve disease. By focusing on transcatheter valve replacement technologies, JenaValve addresses significant unmet needs in the cardiovascular market, positioning itself as a key player in the evolution of structural heart therapies.
The company's market position is bolstered by a long-standing commitment to research and development, supported by a diverse syndicate of venture capital and private equity backers. This institutional support has enabled the firm to navigate the complex regulatory and clinical pathways inherent in the medical device sector, ensuring that its technological advancements translate into tangible patient outcomes.
How much funding has JenaValve raised?
JenaValve has raised a total of $283.3M across 8 funding rounds:
Series A
$14M
Private Equity
$13.5M
Series B
$19M
Private Equity
$10M
Private Equity
$9.4M
Debt
$4.9M
Other Financing Round
$50M
Series C
$162.5M
Series A (2007): $14M with participation from Edmond de Rothschild Investment Partners and Atlas Venture
Private Equity (2010): $13.5M, investors not publicly disclosed
Series B (2010): $19M supported by Gimv, Sunstone Capital, and VI Partners AG
Private Equity (2016): $10M, investors not publicly disclosed
Private Equity (2017): $9.4M, investors not publicly disclosed
Debt (2018): $4.9M, investors not publicly disclosed
Other Financing Round (2020): $50M led by Bain Capital LP, Andera Partners, VI Partners AG, Gimv, RMM Solutions Inc, NeoMed Management, Legend Capital Co. Ltd, and Valiance Asset Management Limited
Series C (2022): $162.5M supported by Andera Partners, Gimv, Bain Capital Life Sciences, and Valiance Advisors
Key Investors in JenaValve
Andera Partners
A Paris-based private equity firm with a dedicated life sciences team that manages over 3.5 billion in assets, focusing on biotech and medtech innovation.
Gimv
A European investment company specializing in long-term partnerships with mid-market businesses across the healthcare and life sciences sectors.
Atlas Venture
A pioneering early-stage venture capital firm that builds breakthrough biotechnology companies by translating cutting-edge science into life-changing medicines.
What's next for JenaValve?
Looking ahead, the strategic deployment of the $162.5M capital is expected to focus on scaling clinical trials and refining manufacturing processes to meet increasing demand. As the company transitions through its current lifecycle stage, the emphasis will likely shift toward commercialization readiness and the expansion of its intellectual property portfolio. The continued involvement of high-caliber investors suggests a clear path toward long-term value creation, with potential for further market penetration in both U.S. and international territories. JenaValve remains a focal point for stakeholders monitoring the next generation of structural heart interventions.
See full JenaValve company page
